Matthew Feng, MD
Ophthalmology · Indianapolis, INNPI 1851520415
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (40.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Dompe US, Inc. at 58.6% of the total. Reporting peaked in 2020 at $5,919 and has fallen 97.6% since, to $140 in 2025. Among ophthalmology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 131 payments — averaging $168.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dompe US, Inc.$13K
- GSK$2K
- Lensar, Inc.$1K
- Eyevance Pharmaceuticals LLC$1K
- Dutch Ophthalmic Research Center (international) B.v.$750
- Johnson & Johnson Surgical Vision, Inc.$475
- plus $3K from 27 others
Across 4 payments — averaging $1312.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kowa Research Institute, Inc.$3K
- Ophtec USA, Inc.$2K
What the payments were for
- Consulting fees$7,20033%
- Speaking & faculty fees$8,85340%
- Food & beverage$6,00627%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dompe US, Inc. | 22 | $12,929 |
| GSK | 1 | $1,625 |
| Lensar, Inc. | 5 | $1,491 |
| Eyevance Pharmaceuticals LLC | 5 | $1,330 |
| Dutch Ophthalmic Research Center (international) B.v. | 1 | $750 |
| Johnson & Johnson Surgical Vision, Inc. | 12 | $475 |
| Alcon | 10 | $475 |
| Ophtec USA, Inc. | 1 | $393 |
| Glaukos Corporation | 3 | $357 |
| Rxsight Inc | 7 | $230 |
| AbbVie(2 entities) | 11 | $208 |
| Eyepoint US, Inc. | 2 | $207 |
| Bausch & Lomb Americas Inc. | 5 | $180 |
| Carl Zeiss Meditec, Inc. | 2 | $158 |
| Aerie Pharmaceuticals, Inc. | 3 | $153 |
| Ivantis, Inc | 2 | $150 |
| Sight Sciences, Inc. | 1 | $126 |
| Shire North American Group Inc | 2 | $126 |
| Biotissue Holdings Inc. | 6 | $100 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $91 |
| Novartis | 5 | $83 |
| Harrow Eye, LLC | 2 | $73 |
| Tarsus Pharmaceuticals, Inc. | 4 | $67 |
| Mallinckrodt Hospital Products Inc. | 2 | $54 |
| Ocular Therapeutix, Inc. | 1 | $46 |
| Omeros Corporation | 2 | $36 |
| Sun Pharmaceutical Industries Inc. | 2 | $33 |
| Carl Zeiss Meditec USA, Inc. | 2 | $28 |
| Rayner Intraocular Lenses Limited | 1 | $23 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Oyster Point Pharma, Inc. | 1 | $15 |
| Kala Pharmaceuticals, Inc. | 1 | $14 |
| Thea Pharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Oxervate$12,660
- LENSAR LASER SYSTEM$1,476
- Flarex$1,250
- EVA, combined machine$750
- TISSUEBLUE$750
- iStent infinite Trabecular Micro-Bypass System Model iS3$345
- iS3-iStent infiniteTrabecular Micro-Bypass System Model iS3$173
- AcrySof IQ VIVITY IOL$139
- Hydrus Microstent$136
- OMNI(R) SURGICAL SYSTEM (US)$126
- DEXYCU$125
- Rhopressa$122
- Rocklatan$122
- XIIDRA$107
- MIEBO$102
How this compares
$22,059 in reported general payments places this provider in the 95th percentile of 266 ophthalmology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 48 | $1,745,588 |
| XiidraLifitegrast | 63 | $59,505 |
| RestasisCyclosporine | 38 | $39,941 |
| Prednisolone Acetate | 507 | $23,040 |
| Fluorometholone | 253 | $22,522 |
| MieboPerfluorohexyloctane/Pf | 17 | $16,105 |
| VevyeCyclosporine | 16 | $12,123 |
| CequaCyclosporine | 12 | $10,444 |
| LumiganBimatoprost | 22 | $8,114 |
| ValacyclovirValacyclovir Hcl | 84 | $8,063 |
| TyrvayaVarenicline Tartrate | 11 | $7,217 |
| RocklatanNetarsudil Mesylat/Latanoprost | 21 | $6,996 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 20 | $4,181 |
| RhopressaNetarsudil Mesylate | 13 | $4,142 |
| Ofloxacin | 322 | $3,656 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $12,929 | $1,745,58848 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $180 | $75,61180 claims |
| AbbVieRestasis, Lumigan | $208 | $48,05560 claims |
| Harrow Eye, LLCVevye | $73 | $12,12316 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $153 | $11,13834 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $33 | $10,44412 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $15 | $7,21711 claims |
| AlconSimbrinza | $475 | $4,18120 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $91 | $2,71615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 266 ophthalmology providers in Indiana.
Other ophthalmology in Indianapolis
- Kevin WaltzIndianapolis$199K
- Janet HummerIndianapolis$96K
- Francis PriceIndianapolis$67K
- Michael OrrIndianapolis$26K
- John LindIndianapolis$20K
- Shaohui LiuIndianapolis$19K
- John LatonaIndianapolis$18K
- William WhitsonIndianapolis$15K
- Thierry WilbrandtIndianapolis$13K
- Anthony LombardoIndianapolis$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.